sever
acut
respiratori
infect
respons
coronaviru
spread
global
lead
devast
loss
life
short
month
clinic
scientif
commun
ralli
rapidli
evolv
understand
mechan
diseas
potenti
therapeut
review
discuss
current
understand
basi
virolog
epidemiolog
clinic
manifest
includ
cardiovascular
mortal
detail
review
viral
life
cycl
put
mechan
injuri
frame
discuss
possibl
prevent
therapeut
strategi
ongo
unpreced
collect
effort
without
doubt
advanc
abil
prevent
spread
optim
care
patient
suffer
coronaviru
contagi
diseas
caus
sever
acut
respiratori
syndrom
reach
pandem
statu
spread
across
world
overwhelm
healthcar
system
strangl
global
economi
led
devast
loss
life
widespread
effort
regul
clinician
scientist
drive
rapid
expans
knowledg
viru
diseas
review
current
data
focu
basic
understand
mechan
diseas
translat
clinic
syndrom
potenti
therapeut
discuss
basic
virolog
epidemiolog
clinic
manifest
multiorgan
consequ
outcom
focu
cardiovascular
complic
propos
sever
mechan
injuri
virolog
potenti
mechan
injuri
form
basi
discuss
potenti
diseasemodifi
therapi
coronaviru
covid
contagi
diseas
caus
sever
acut
respiratori
syndrom
reach
pandem
statu
spread
across
world
overwhelm
healthcar
system
strangl
global
economi
led
devast
loss
life
ongo
wake
world
medic
scientif
commun
come
togeth
rapidli
expand
knowledg
pathogenesi
review
bodi
work
focu
basic
understand
mechan
diseas
translat
clinic
syndrom
potenti
therapeut
option
specif
discuss
basic
virolog
epidemiolog
clinic
manifest
includ
present
progress
multiorgan
consequ
outcom
focu
cardiovascular
complic
propos
sever
potenti
mechan
injuri
discuss
rang
possibl
therapeut
option
context
viral
life
cycl
possibl
mechan
injuri
final
recognit
scale
crisi
address
ethic
consider
around
standard
care
event
resourc
scarciti
remain
third
cov
genom
encod
structur
protein
varieti
accessori
protein
latter
discuss
structur
protein
constitu
protein
transmiss
viral
particl
virion
key
structur
cov
protein
nucleocapsid
protein
n
three
transmembran
protein
spike
protein
membran
protein
envelop
protein
e
figur
protein
respons
viruscel
receptor
interact
figur
e
protein
respons
membran
structur
fusion
n
protein
bind
viral
rna
mediat
interact
e
protein
genom
encapsul
life
cycl
rigor
establish
howev
given
consider
sequenc
homolog
presum
similar
cov
gener
cov
life
cycl
consist
seri
step
begin
viral
bind
target
cell
culmin
viral
reproduct
knowledg
process
inform
understand
viral
physiolog
also
serv
basi
discuss
antivir
therapeut
figur
aim
evolv
therapeut
break
link
chain
viral
life
cycl
order
forestal
propag
infect
within
cell
individu
patient
known
bind
cell
via
receptor
membranebound
glycoprotein
angiotensin
convert
enzym
observ
bind
cov
receptor
name
dipeptidyl
peptidas
aminopeptidas
n
apn
bind
viru
intern
via
endocytosi
without
access
host
intracellular
compart
membran
fusion
event
occur
figur
process
mediat
least
part
anoth
membran
bound
proteas
known
transmembran
serin
proteas
cleav
protein
necessari
step
membran
fusion
interestingli
proteas
activ
cov
receptor
apn
seem
necessari
membran
fusion
upon
membran
fusion
viral
rna
genom
enter
intracellular
compart
point
viral
rna
may
translat
encod
structur
nonstructur
protein
translat
nonstructur
protein
replicas
result
product
singl
massiv
polypeptid
chain
sixteen
constitu
nonstructur
protein
cleav
process
initi
mediat
intracellular
proteas
propag
function
cov
main
proteas
papainlik
proteas
anoth
replicas
protein
rnadepend
rna
polymeras
rdrp
respons
replic
amplif
viral
genom
process
mutat
may
acquir
error
replic
recombin
event
upon
amplif
viral
rna
viral
structur
nonstructur
protein
may
gener
viral
structur
protein
transmembran
natur
except
n
protein
target
er
membran
appropri
signal
sequenc
viral
rna
bound
n
protein
interact
structur
protein
membran
er
golgi
apparatu
anoth
membran
fusion
event
membran
result
viral
bud
exocytosi
importantli
precis
molecular
differ
account
import
clinic
differ
infect
prolong
latenc
wide
variabl
symptom
possibl
predisposit
individu
preexist
cardiovascular
condit
predilect
myocardi
complic
remain
unclear
sarscov
viru
caus
mild
respiratori
infect
known
employ
receptor
given
function
cardiovascular
system
import
angiotensindirect
pharmacolog
cardiovascular
diseas
appar
propens
sever
ill
among
patient
cardiovascular
comorbid
molecul
subject
much
attent
inde
major
clinic
societi
issu
consensu
statement
use
ace
inhibitor
acei
angiotensinreceptor
blocker
arb
set
pandem
discuss
later
angiotensinconvert
enzym
singlepass
transmembran
protein
proteas
activ
cleav
vasoconstrictor
angiotensin
ii
vasodil
angiotensin
function
counterregulatori
enzym
function
gener
angiotensin
ii
human
protein
broad
pattern
express
found
lung
epithelium
particular
type
ii
pneumocyt
myocardium
endothelium
gi
tract
bone
marrow
kidney
spleen
among
tissu
potenti
explain
multiorgan
injuri
observ
infect
anoth
relev
featur
gene
express
encod
x
chromosom
may
account
possibl
sex
differ
observ
epidemiolog
anim
model
acut
respiratori
distress
syndrom
ard
due
chemic
pneumon
overwhelm
sepsi
endotoxemia
influenza
ko
mice
sever
acut
lung
injuri
ali
rel
wildtyp
counterpart
evalu
histolog
measur
elast
phenotyp
increas
elast
rescu
administr
recombin
human
affirm
causal
link
defici
profound
state
ali
addit
administr
losartan
angiotensin
ii
receptor
r
blocker
mitig
exacerb
effect
sarscov
spike
protein
anim
model
ard
losartan
also
abrog
sever
ali
due
influenza
mice
regard
counterregulatori
properti
effect
appear
rescu
mice
exampl
effect
result
sever
ali
abrog
ko
mice
demonstr
sever
ali
ko
reduct
sever
observ
ko
doserespons
also
impli
causat
compar
effect
seen
myocardi
dysfunct
ko
ko
evid
contractil
deficit
observ
ko
mice
note
case
howev
anim
model
constitut
knockout
system
rather
lineagespecif
induc
knockout
thu
cell
mediat
phenotyp
abnorm
determin
abl
util
isoform
swine
bat
civet
human
suggest
mechan
wherebi
viru
may
initi
transmiss
speci
speci
mutat
evolv
novel
pathogen
notabl
murin
function
receptor
therebi
requir
transgen
express
human
mice
use
research
model
undergo
cleavag
membranebound
proteas
result
releas
solubl
blood
stream
effect
solubl
unclear
human
howev
appear
favor
effect
lung
function
model
ard
influenza
rsv
infect
solubl
studi
phase
ii
trial
ard
largescal
wellpow
clinic
outcom
trial
need
research
ongo
determin
whether
solubl
may
act
specif
therapeut
role
decoy
receptor
discuss
later
final
given
necess
viral
infect
role
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
drawn
intens
attent
importantli
enzym
inhibit
aceiarb
use
acei
arb
exposur
may
result
protein
upregul
anim
model
howev
anim
model
exhibit
effect
exist
epidemiolog
among
patient
take
acei
arb
confound
cardiovascular
comorbid
may
alter
angiotensin
ii
express
time
unclear
acei
arb
use
influenc
receptor
express
whether
variabl
express
impact
propens
sever
infect
exposur
huanan
seafood
market
common
among
earliest
case
contribut
epidem
china
suggest
zoonot
diseas
substanti
transmiss
asymptomat
host
facilit
widespread
transmiss
contribut
pandem
potenti
studi
singapor
extens
contact
trace
identifi
cluster
case
secondari
spread
infect
occur
day
prior
symptom
develop
sourc
patient
thu
contain
measur
aim
sole
isol
symptomat
individu
inadequ
furthermor
contact
trace
effort
take
account
presymptomat
contagi
period
comprehens
captur
potenti
expos
individu
r
static
measur
intervent
includ
selfquarantin
contact
isol
social
distanc
enhanc
hygien
measur
proven
effect
china
follow
implement
measur
china
r
steadili
decreas
prior
januari
rd
period
januari
burden
viru
evolv
rapidli
sinc
first
appear
wuhan
china
decemb
began
case
report
atyp
pneumonia
span
globe
pandem
present
publish
data
come
china
form
basi
understand
epidemiolog
largest
publish
registri
date
chines
center
diseas
control
prevent
cdc
report
highlevel
detail
patient
characterist
sever
manifest
surviv
case
put
confirm
popul
predominantli
identifi
presenc
symptom
case
occur
children
year
age
suggest
children
either
either
resist
infect
rare
symptomat
confirm
case
mild
defin
mild
pneumonia
sever
signific
infiltr
sign
respiratori
compromis
critic
respiratori
failur
eg
mechan
ventil
shock
multiorgan
system
failur
first
confirm
case
us
identifi
januari
us
surpass
countri
absolut
number
case
howev
given
rapid
recent
onset
burden
publish
data
reflect
experi
us
earli
snap
shot
us
cdc
confirm
case
symptom
exposur
occur
age
data
rapidli
accumul
much
epidemiolog
viru
remain
unknown
public
small
singl
center
studi
detail
clinic
characterist
complic
outcom
subset
patient
hospit
result
limit
test
data
suggest
mani
infect
individu
may
asymptomat
true
burden
infect
individu
unclear
underestim
variabl
manifest
symptom
hamper
public
health
initi
trace
isol
infect
individu
also
limit
abil
accur
estim
infect
symptom
burden
nonfat
fatal
complic
rate
overal
popul
infect
individu
caveat
publish
data
provid
insight
vulner
atrisk
popul
requir
hospit
individu
studi
small
predictor
sever
manifest
poor
outcom
gener
consist
detail
multicent
case
seri
hospit
patient
china
common
symptom
fever
follow
cough
fatigu
sputum
product
short
breath
less
common
symptom
includ
headach
myalgia
sore
throat
nausea
vomit
diarrhea
american
associ
otolaryngolog
recent
highlight
anosmia
dysgeusia
possibl
symptom
diseas
well
median
incub
period
time
probabl
exposur
first
symptom
day
iqr
anoth
report
detail
infect
patient
develop
symptom
within
day
common
lab
derang
admiss
includ
lymphopenia
elev
creactiv
protein
lactat
dehydrogenas
liver
transaminas
ddimer
notabl
procalcitonin
rare
elev
data
gener
consist
across
multipl
smaller
studi
sever
note
elev
inflammatori
marker
ferritin
esr
evid
cardiac
kidney
injuri
admiss
variabl
across
studi
tend
absent
upon
hospit
chest
comput
tomographi
time
admiss
abnorm
patient
ground
glass
opac
local
patchi
shadow
mani
sever
manifest
ard
acut
kidney
injuri
aki
myocardi
injuri
tend
occur
mani
day
onset
symptom
portend
wors
outcom
within
hospit
popul
rate
icu
admiss
rang
across
studi
sever
studi
identifi
older
age
baselin
burden
comorbid
diabet
hypertens
prior
coronari
diseas
prior
lung
diseas
predictor
signific
diseas
progress
higher
rate
ard
aki
cardiac
injuri
icu
admiss
death
increas
marker
inflamm
coagul
cardiac
injuri
also
correl
diseas
sever
rise
throughout
cours
diseas
hospit
popul
time
death
occur
median
day
ill
onset
median
time
symptom
onset
discharg
survivor
around
week
promin
complic
respiratori
failur
previous
describ
major
patient
mild
symptom
hospit
patient
respiratori
symptom
common
rang
sever
cough
dyspnea
ard
ard
rate
largest
case
seri
may
underestim
due
short
averag
follow
time
day
vast
major
patient
remain
hospit
end
studi
ard
tend
occur
week
ill
often
precipit
protract
reason
avoid
risk
provid
infect
emerg
intub
profession
societi
recommend
earli
intub
event
respiratori
declin
intub
requir
variou
chines
seri
howev
rate
highflow
nasal
cannula
noninvas
mechan
ventil
also
high
therapi
believ
result
aerosol
gener
recommendedconsequ
patient
intub
unabl
support
nasal
cannula
nonrebreath
mask
older
age
baselin
hypertens
diabet
high
fever
lymphopenia
injuri
organ
eg
aki
ali
elev
ddimer
inflammatori
marker
predictor
ard
advanc
age
neutropenia
elev
ddimer
inflamm
associ
higher
mortal
ard
develop
ard
along
acut
cardiac
injuri
independ
predictor
death
importantli
hypoxem
respiratori
failur
lead
caus
death
contribut
death
estim
vari
incid
acut
kidney
injuri
rang
among
hospit
patient
rate
proteinuria
hematuria
appear
even
higher
acut
kidney
injuri
occur
first
day
admiss
patient
baselin
chronic
kidney
diseas
day
patient
normal
baselin
renal
function
mechan
renal
injuri
hypothes
includ
acut
tubular
necrosi
atn
direct
cytotox
effect
viru
immunemedi
damag
transamin
common
incid
high
patient
critic
ill
surviv
acut
liver
injuri
defin
either
alanin
aminotransferas
aspart
aminotransferas
greater
three
time
upper
limit
normal
occur
less
frequent
report
occur
patient
admit
icu
washington
state
numer
studi
report
acut
cardiac
injuri
import
manifest
covid
studi
publish
date
acut
cardiac
injuri
variabl
defin
either
cardiac
troponin
elev
th
percentil
alon
composit
troponin
elev
ecg
echocardiograph
abnorm
importantli
mani
aspect
endpoint
remain
undefin
includ
frequenc
sever
associ
structur
abnorm
report
rate
cardiac
injuri
vari
studi
hospit
patient
number
like
partial
depend
upon
definit
use
sever
case
hospit
data
drawn
notabl
patient
evid
cardiac
injuri
tend
older
comorbid
includ
baselin
hypertens
diabet
coronari
heart
diseas
heart
failur
across
studi
cardiac
injuri
associ
wors
outcom
includ
icu
admiss
death
base
serial
assess
troponin
research
china
report
median
time
develop
acut
cardiac
injuri
day
iqr
ill
onset
occur
develop
ard
note
earli
cardiac
injuri
report
even
absenc
respiratori
symptom
case
seri
shi
et
al
mortal
rate
hospit
subsequ
evid
cardiac
injuri
significantli
higher
without
cardiac
injuri
vs
p
along
ard
independ
predictor
death
magnitud
troponin
elev
correl
modestli
degre
hscrp
elev
dynam
increas
troponin
associ
higher
mortal
rate
importantli
mechan
cardiac
injuri
may
multifactori
includ
demandischemia
toxic
direct
viral
injuri
stress
inflamm
microvascular
dysfunct
plaqu
ruptur
discuss
later
central
illustr
arrhythmia
note
sever
publish
report
case
seri
hospit
patient
develop
unspecifi
arrhythmia
hospit
higher
rate
note
among
patient
admit
icu
case
seri
hospit
patient
provid
insight
specif
arrhythmia
report
sustain
ventricular
tachycardia
ventricular
fibril
amongst
patient
find
consist
arrhythmia
document
influenza
known
caus
av
node
dysfunct
ventricular
arrhythmia
heart
failur
myocardi
dysfunct
describ
case
seri
patient
heart
failur
note
complic
patient
among
nonsurvivor
though
definit
heart
failur
clearli
detail
gener
pattern
fatal
across
age
group
appear
consist
throughout
world
gener
greater
age
associ
greater
risk
sever
diseas
well
death
accord
chines
cdc
report
case
agerel
cfr
follow
mention
prior
section
patient
present
highli
variabl
acuiti
diseas
diseas
progress
cardiac
injuri
common
featur
diseas
process
patient
die
myocardi
injuri
proxim
find
multipl
therapi
current
develop
trial
treatment
discuss
later
section
understand
mechan
cardiac
diseas
vital
effect
time
target
treatment
syndrom
devast
sequela
propos
sever
put
mechan
cardiovascular
diseas
central
illustr
presenc
receptor
myocardium
vascular
endotheli
cell
provid
theoret
mechan
direct
viral
infect
heart
result
myocard
report
document
clear
case
myocard
syndrom
howev
date
report
biopsi
proven
viral
myocard
viral
inclus
viral
dna
detect
myocardi
tissu
close
relat
document
caus
viral
myocard
detect
viral
rna
autopsi
heart
light
share
host
cell
entri
receptor
direct
viral
myocardi
entri
result
injuri
plausibl
well
anoth
hypothes
mechan
direct
viral
injuri
myocardium
infectionmedi
vascul
receptor
highli
express
arteri
venou
endotheli
cell
patholog
data
show
evid
vascul
monocyt
lymphocyt
infiltr
vascular
endotheli
cell
injuri
stromal
edema
heart
either
direct
viral
entri
myocardi
endotheli
cell
could
trigger
vascul
presenc
viru
could
lead
indirect
immunolog
respons
result
hypersensit
reaction
insult
would
associ
myocardi
injuri
perhap
even
overt
myocardi
dysfunct
microand
macrothrombos
observ
autopsi
evalu
patient
die
promin
find
disarray
coagul
fibrinolyt
system
nonsurvivor
meet
criteria
dic
may
hypothes
myocardi
injuri
result
microthrombu
format
myocardi
vasculatur
set
hypercoagul
state
like
dic
infect
sepsi
lead
caus
dic
gener
exact
mechan
dic
set
sepsi
ard
complex
gener
thought
relat
immunemedi
exhaust
coagul
fibrinolyt
system
promot
bleed
thrombosi
patient
endotheli
injuri
inflammatori
cytokin
tnfalpha
upregul
tissu
factor
express
drive
prothombot
state
dysregul
antithrombin
iii
plasminogen
activ
inhibitor
type
protein
c
set
signific
inflamm
sepsi
promot
anticoagul
state
furthermor
platelet
activ
also
ensu
context
sepsi
inflamm
tip
fine
balanc
coagul
system
summari
hyperinflamm
immun
activ
seen
sever
infect
like
suffici
trigger
dic
microvascular
dysfunct
myocardi
injuri
role
stress
takotsubo
cardiomyopathi
relat
cardiac
injuri
known
time
case
literatur
current
howev
sever
propos
mechan
relat
cardiac
injuri
detail
review
also
thought
implic
pathophysiolog
stress
cardiomyopathi
particularli
microvascular
dysfunct
cytokin
storm
sympathet
surg
discuss
myocardi
injuri
would
incomplet
without
address
issu
acut
coronari
syndrom
ac
myocardi
infarct
mi
current
publish
experi
detail
incid
ac
epicardi
plaqu
ruptur
mechan
acut
cardiac
injuri
observ
howev
histor
preced
associ
infect
elev
risk
ac
epidemiolog
studi
shown
hospit
pneumonia
associ
higher
risk
atherosclerot
event
influenza
infect
well
studi
shown
tempor
associ
cardiovascular
complic
acut
coronari
syndrom
annual
vaccin
season
influenza
associ
lower
rate
major
advers
cardiovascular
event
metaanalysi
clinic
trial
evalu
question
therefor
viral
infect
associ
increas
risk
coronari
event
prevent
reduct
risk
therefor
plausibl
ac
also
import
caus
acut
cardiac
injuri
patient
accordingli
intern
societi
devis
pathway
protocol
effect
treat
patient
ac
includ
appropri
time
use
resourc
ensur
best
outcom
patient
also
maintain
provid
safeti
exampl
may
lead
higher
risk
plaqu
destabil
ac
inflamm
may
lead
vasoconstrict
coronari
bed
chang
put
mechan
infect
could
lead
destabil
preexist
atherosclerot
plaqu
drive
acut
coronari
event
period
sever
physiolog
stress
set
sepsi
respiratori
failur
associ
elev
biomark
myocardi
injuri
strain
patient
entiti
confer
poorer
prognosi
mechan
myocardi
injuri
thought
relat
mismatch
oxygen
suppli
demand
without
acut
atherothrombot
plaqu
disrupt
consist
diagnosi
type
myocardi
infarct
mi
inde
patient
suffer
type
mi
compar
type
mi
higher
mortal
rate
may
part
explain
higher
burden
acut
chronic
comorbid
condit
type
mi
popul
furthermor
type
mi
background
coronari
arteri
diseas
cad
wors
prognosi
patient
without
cad
given
age
comorbid
profil
patient
hospit
sever
reason
assum
popul
higher
risk
underli
nonobstruct
cad
therefor
presenc
type
mi
popul
like
marker
contributor
poor
outcom
patient
troponin
elev
perhap
one
intrigu
mechan
cardiac
injuri
sever
patient
observ
basi
sever
investig
therapi
includ
steroid
antiinflammatori
agent
discuss
later
prior
studi
shown
cardiomyopathi
sepsi
partial
mediat
inflammatori
cytokin
recombin
result
earli
sustain
lv
systol
dysfunct
canin
cultur
rat
cardiomyocyt
demonstr
reduc
contractil
expos
mechan
may
modul
calcium
channel
activ
result
myocardi
dysfunct
addit
nitric
oxid
also
believ
mediat
myocardi
depress
hyperinflammatori
state
sepsi
semin
studi
found
medium
lpsactiv
macrophag
suppress
myocyt
contractil
find
revers
synthas
inhibitor
lnmonomethyl
arginin
final
recent
understand
key
role
mitochondri
dysfunct
septic
state
rais
question
role
entiti
sepsi
associ
cardiomyopathi
inde
similar
mechan
thought
possibl
underli
pathophysiolog
stress
takotsubo
cardiomyopathi
well
preced
review
viral
physiolog
variou
potenti
mechan
injuri
host
serv
basi
consid
specif
target
treatment
prevent
follow
section
outlin
sever
current
candid
class
agent
includ
brief
discuss
vaccin
develop
figur
antivir
mechan
nucleotid
analog
interfer
rdrp
function
viral
genom
replic
amplif
figur
covspecif
drug
avail
time
ongo
effort
employ
drug
class
reliant
preexist
agent
design
viral
ill
widelyappli
agent
class
remdesivir
remdesivir
function
chain
termin
rna
replic
initi
design
use
ebola
addit
remdesivir
grow
rna
strand
rdrp
block
incorpor
addit
nucleotid
therebi
halt
genom
replic
agent
shown
vitro
activ
lead
offlabel
investig
use
around
world
multipl
randomizedcontrol
trial
ongo
china
unit
state
moder
sever
critic
anoth
nucleotid
analog
disrupt
rdrpdepend
viral
replic
favipiravir
investig
approv
sever
countri
addit
agent
studi
includ
emtricitabinetenofovir
ribavirin
antivir
mechan
action
proteas
inhibitor
block
viral
proteas
cleav
nonstructur
protein
larg
monomer
replicas
detail
figur
matur
nonstructur
protein
rdrp
necessari
viral
reproduct
pharmacolog
impair
proteas
effect
stop
viral
replic
random
control
trial
lopinavirritonavir
combin
proteas
inhibitor
design
hiv
treatment
patient
least
moder
significantli
alter
clinic
improv
viral
clearanc
result
trial
met
disappoint
neg
studi
forestal
trial
drug
develop
proteas
inhibitor
therapeut
class
given
drug
specif
design
inde
develop
inhibitor
specif
main
proteas
underway
class
agent
identifi
use
structurebas
drug
design
inhibitor
demonstr
vitro
efficaci
favor
pharmacokinet
candid
proteas
inhibitor
includ
danoprevir
drug
origin
intend
hcv
therapi
order
viral
genom
gain
access
cellular
machineri
replic
membran
fusion
event
must
occur
viral
endosom
membran
noncoval
bound
interact
protein
exact
mechan
membran
fusion
unknown
appear
depend
endosom
matur
membranebound
host
proteas
antivir
properti
chloroquin
cq
previous
observ
hiv
virus
cq
hcq
thought
inhibit
endosom
matur
process
endosom
transloc
perimembran
region
cell
central
hub
figur
cq
prevent
viral
replic
vitro
followup
studi
demonstr
compar
efficaci
hcq
less
toxic
deriv
suggest
mechan
impair
endosom
matur
inde
appli
infect
vitro
poorqual
nonrandom
unblind
data
exist
assess
benefit
hcq
hcq
wide
use
fda
emerg
author
data
need
prove
efficaci
human
notabl
cq
hcq
prolong
qt
may
induc
arrhythmia
signific
caution
use
start
agent
patient
qtc
ms
concomit
use
qt
prolong
agent
recommend
camostat
proteas
inhibitor
approv
treatment
chronic
pancreat
camostat
appear
inhibit
proteom
vitro
studi
random
placebocontrol
trial
underway
agent
figur
neutral
antibodi
design
bind
virion
prevent
viral
exposur
bind
host
cell
figur
plasma
patient
recov
may
contain
igg
antibodi
small
singlearm
trial
convalesc
plasma
patient
ard
clinic
improv
patient
wean
ventil
addit
trial
ongo
better
defin
safeti
efficaci
strategi
isol
specif
neutral
antibodi
clonal
techniqu
appeal
strategi
provid
target
therapi
potenti
lower
risk
advers
event
strategi
current
investig
includ
antibodi
clone
convalesc
serum
individu
recov
synthet
antibodi
unclear
whether
differ
protein
may
limit
effect
antibodi
clone
patient
convalesc
synthet
antibodi
repres
excit
novel
therapeut
avenu
one
strategi
explor
fuse
fc
igg
hypothesi
synthet
antibodi
would
serv
decoy
receptor
prevent
cellular
bind
virion
similar
vein
studi
ongo
decoy
protein
design
act
viral
sink
preliminari
success
strategi
use
solubl
human
central
illustr
advanc
stage
liken
cytokin
storm
syndrom
nonspecif
widespread
immun
activ
elev
level
inflammatori
biomark
hscrp
identifi
patient
high
risk
progress
sever
diseas
death
immunomodulatori
antiinflammatori
therapi
use
despit
limit
data
patient
evid
hyperinflamm
effort
curb
patholog
immun
activ
elev
patient
sever
prompt
consider
use
inhibitor
tocilizumab
siltuximab
extrapol
treatment
cytokin
releas
syndrom
azithromycin
macrolid
antibiot
long
tout
antiinflammatori
effect
use
adjunct
therapi
treatment
commun
acquir
pneumonia
chronic
obstruct
pulmonari
diseas
exacerb
limit
data
suggest
adjunct
azithromycin
moderatesever
ard
associ
improv
outcom
small
nonrandom
studi
show
combin
azithromycin
hydroxychloroquin
associ
effect
clearanc
patient
compar
either
monotherapi
hydroxychloroquin
standard
care
howev
numer
limit
studi
render
data
uninterpret
antiinflammatori
pleiotrop
effect
statin
cultiv
differ
patholog
state
statin
shown
murin
model
acut
lung
injuri
human
attenu
inflammatori
compon
acut
lung
injuri
multicent
random
trial
simvastatin
patient
versatil
caus
ard
show
differ
compar
placebo
ventil
free
day
multiorgan
failur
mortal
subsequ
studi
subphenotyp
trial
popul
hyper
vs
hypoinflammatori
ard
found
statist
signific
improv
surviv
simvastatin
hyperinflammatori
group
posthoc
analysi
jupit
trial
observ
reduct
incid
pneumonia
rosuvastatin
benefit
statin
therapi
hyperinflammatori
state
advanc
unknown
discoveri
safe
efficaci
vaccin
clearli
aspir
prevent
strategi
intens
effort
ongo
employ
numer
approach
acceler
test
believ
structur
protein
e
n
protein
may
serv
antigen
neutral
antibodi
cell
respons
base
experi
vaccin
develop
seem
promis
candid
target
protein
induc
humor
protect
cellular
immun
encouragingli
administr
fulllength
bind
domain
protein
induc
highli
potent
neutral
antibodi
convey
protect
immun
anim
model
estim
suggest
happen
itali
spain
burden
far
outstrip
healthcar
capac
us
global
insuffici
avail
hospit
icu
bed
capac
healthcar
provid
specif
therapeut
support
intervent
mechan
ventil
renal
replac
reason
organ
italian
societi
anesthesia
analgesia
resuscit
intens
care
siaarti
individu
healthcar
institut
develop
guidanc
alloc
resourc
event
adequ
addit
resourc
obtain
effort
build
set
principl
establish
wake
pandem
time
us
depart
health
human
servic
commiss
institut
medicin
iom
provid
expert
guidanc
implement
altern
standard
healthcar
set
disast
report
iom
defin
principl
crisi
standard
care
defin
substanti
chang
usual
healthcar
oper
includ
level
care
possibl
deliv
set
pervas
catastroph
disast
notabl
framework
recogn
formal
declar
crisi
standard
care
oper
enabl
specif
legalregulatori
power
protect
healthcar
provid
necessari
task
alloc
use
scarc
medic
resourc
appreci
distress
associ
alloc
scarc
medic
resourc
iom
recommend
process
guid
seven
ethic
principl
fair
duti
care
duti
steward
resourc
transpar
consist
proportion
account
work
principl
ethicist
come
gener
consensu
goal
maxim
benefit
maintain
equiti
object
transpar
maxim
benefit
ideal
involv
preserv
live
well
lifeyear
acknowledg
import
prognosi
practic
applic
principl
challeng
appear
gener
agreement
across
literatur
number
concept
recommend
develop
triag
score
system
account
acut
premorbid
prognosi
order
alloc
scarc
resourc
like
benefit
score
system
util
object
clinic
inform
order
minim
need
clinic
judgement
risk
introduc
inconsist
bia
use
system
determin
stem
transpar
provid
patient
famili
triag
appli
broadli
patient
requir
particular
resourc
suffer
pandem
diseas
eg
appli
decis
use
va
ecmo
patient
myocard
due
cardiogen
shock
etiolog
random
system
eg
lotteri
use
break
tie
case
similar
estim
prognosi
rather
firstcomefirst
serv
approach
importantli
mani
advoc
independ
triag
physician
make
determin
remov
burden
bedsid
healthcar
team
triag
physician
may
support
necessari
triag
committe
compris
expert
area
ethic
relev
medic
field
area
controversi
includ
whether
prioriti
allow
healthcar
provid
ethicist
argu
priorit
unlik
recoveri
time
frame
would
allow
continu
profession
respons
other
argu
grant
prioriti
recogn
assumpt
risk
also
encourag
ongo
particip
patient
care
along
line
argument
also
made
priorit
research
particip
optim
tool
prognost
also
remain
elus
sequenti
organ
failur
assess
sofa
score
suggest
quantit
assess
acut
ill
sever
howev
recognit
tool
may
well
calibr
popul
could
lead
inaccur
assess
prognosi
valu
predetermin
framework
commun
provid
engag
establish
legal
author
logist
oper
prepared
clear
nevertheless
acknowledg
prospect
largescal
ration
healthcar
heartbreak
foreign
civilian
healthcar
provid
develop
countri
short
month
spread
across
world
distress
speed
threaten
global
econom
individu
health
wellb
mani
region
healthcar
system
overwhelm
underresourc
forc
clinician
administr
make
previous
unthink
decis
regard
alloc
medic
care
howev
wake
devast
clinician
scientist
ralli
togeth
rapidli
evolv
understand
aspect
infect
basic
virolog
human
manifest
therapeut
prevent
strategi
unpreced
collect
effort
without
doubt
advanc
abil
prevent
spread
optim
care
patient
suffer
golgi
apparatu
form
viral
capsid
viral
assembl
occur
addit
viral
rna
n
protein
associ
transmembran
viral
protein
exocytosi
result
releas
newli
synthes
viral
particl
mi
denot
myocardi
infarct
ascvd
atherosclerot
cardiovascular
diseas
dic
dissemin
intravascular
coagul
